Pfizer Inc

To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

On June 21, Anthem (ANTM) filed a bear hug letter for Cigna (CI). A bear hug letter is a formal press release in which an acquiring company discloses its interest in a target company.

Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.

In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.

In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.

Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.

As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.

In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

On Nov. 9, Pfizer announced that its coronavirus vaccine is more than 90 percent effective. Who owns Pfizer and where is the company based?

The Pfizer-BioNTech vaccine holds life-changing potential. Who are the owners that are running the show?

Albert Bourla, CEO of pharmaceutical giant Pfizer, has said there is a 60 percent chance that the company's scientists will know whether their vaccine is effective by the end of October.

The U.S. government’s Operation Warp Speed program has already invested billions in six potential coronavirus vaccine candidates.

(continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

On May 14, Jim Simons’ Renaissance Technologies filed its 13F for the first quarter of 2020. The hedge fund reduced its holdings in Tesla.

Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”

While the media caters to Millennial preferences, there’s one economic sector that’s shifting to a more seasoned crowd: healthcare stocks.

AbbVie (ABBV) is currently evaluating more than 20 investigational therapies targeting solid tumors. Seventeen of them are in Phase 1 trials.

Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.

GSK highlighted the prioritization of research and development programs, business development, and new product launches as its key growth drivers in 2018.

According to Pfizer’s fourth-quarter earnings conference call, Ibrance has managed to report global revenues of $4.1 billion in fiscal 2018.

In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.

Pfizer expects its adjusted SI&A expenses to fall by $13.5 billion–$14.5 billion in fiscal 2019—a decline of ~$200 million YoY at the midpoint.

On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.

AI is the buzzword these days, and the market has huge growth potential.

Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the third quarter of 2017.

In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.

Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.

Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.

The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.

Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue.

In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

Gilead Sciences’ Atripla, Genvoya, and Stribild generated revenues of $663.0 million, $2.2 billion, and $361.0 million, respectively, in the first half of 2018.

As discussed, Pfizer’s (PFE) business is divided into two business segments, Innovative Health and Essential Health.

Verzenio has demonstrated double-digit growth in new patient usage in patient segments targeted by the drug’s first two approved indications.

In 1Q18, Johnson & Johnson (JNJ) generated revenue of $20 billion, compared with $17.7 billion in 1Q17.

Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

On April 11, 2018, Pfizer (PFE) said its ATLAS trial with Inlyta failed to show improvement in RCC disease-free survival.